Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity

AstraZeneca

Status and phase: Completed; Early Phase 1

Conditions: Insulin Resistance

Treatments: Drug: Atropine; Drug: Placebo Sodium; Drug: Physostigmine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00689208

D4411M00007

Details and patient eligibility

About

The present study on pharmacological intervention in autonomic nervous dysregulation(parasympathetic dysfunction,) regarding insulin resistance, is a concept testing in humans tohelp identify potential new pharmacological target sites in the central nervous system.

Enrollment: 12 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Signed written informed consent
• BMI of lean and abdominally obese men and women
• weight stable

Exclusion criteria

• Ongoing clinically significant diseases
• History of repeated syncope
• resting pulse<50 or systolic blood pressure <100

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind